SLGL (Sol-Gel Technologies) Common Stock: $1.32 Mil (As of Mar. 2026)


SLGL Sol-Gel Technologies Ltd SLGL
56 GF Score
Price $74.40
GF Value $65.37
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Sol-Gel Technologies Common Stock?

Sol-Gel Technologies SLGL +1.87% 56 Common Stock is $1.32 Mil as of Mar. 2026. GuruFocus rates SLGL with a GF Score™ of 56/100 and a GF Value™ of $65.37 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Sol-Gel Technologies's quarterly common stock stayed the same from Sep. 2025 ($0.77 Mil) to Dec. 2025 ($0.77 Mil) but then increased from Dec. 2025 ($0.77 Mil) to Mar. 2026 ($1.32 Mil).

Sol-Gel Technologies's annual common stock stayed the same from Dec. 2023 ($0.77 Mil) to Dec. 2024 ($0.77 Mil) and stayed the same from Dec. 2024 ($0.77 Mil) to Dec. 2025 ($0.77 Mil).

Sol-Gel Technologies Common Stock Historical Data

* Premium members only.

The historical data trend for Sol-Gel Technologies's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sol-Gel Technologies Common Stock Chart

Sol-Gel Technologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.64 0.64 0.77 0.77 0.77

Sol-Gel Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 0.77 0.77 0.77 1.32
SLGL
56GF Score
Sol-Gel Technologies Ltd SLGL
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sol-Gel Technologies Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $1.32 Mil mean?
Sol-Gel Technologies (SLGL) has a Common Stock of $1.32 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Sol-Gel Technologies and its competitors.
Is Sol-Gel Technologies' Common Stock too high?
Sol-Gel Technologies' current Common Stock is $1.32 Mil. Overall, Sol-Gel Technologies has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sol-Gel Technologies' Common Stock compare to ALEC and LENZ?
Sol-Gel Technologies' Common Stock of $1.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Sol-Gel Technologies and its competitors. Sol-Gel Technologies's current Common Stock is $1.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sol-Gel Technologies stock overvalued right now?
Based on GuruFocus' analysis, Sol-Gel Technologies (SLGL) is currently considered Modestly Overvalued. The stock's GF Value™ is $65.37, compared to a current price of $74.40 — trading 13.8% above its estimated fair value. The current Common Stock is $1.32 Mil. Sol-Gel Technologies' overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Sol-Gel Technologies (SLGL), the current Common Stock is $1.32 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sol-Gel Technologies (SLGL) Overvalued in 2026?

Based on GuruFocus' analysis, Sol-Gel Technologies stock appears to be overvalued. The current stock price of $74.40 is trading 13.8% above its estimated GF Value™ of $65.37. GuruFocus considers Sol-Gel Technologies to be Modestly Overvalued.

Key valuation signals for SLGL:

  • Common Stock: $1.32 Mil
  • GF Value™: $65.37 vs. price of $74.40 (13.8% above fair value)
  • GF Score™: 56/100 with 2 warning signs

No single metric tells the full story. See the SLGL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sol-Gel Technologies Business Description

Other Exchanges 4SG:Germany
Address 7 Golda Meir Street, Weizmann Science Park, Ness Ziona, ISR, 7403650
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
56GF Score

Get the complete analysis for SLGL

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$74.40
Price
$65.37
GF Value